Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer.
Xu L, Si H, Zhuang F, Li C, Zhang L, Zhao Y, Chen T, Dong Y, Wang T, Hou L, Hu T, Sun T, She Y, Hu X, Xie D, Wu J, Wu C, Zhao D, Chen C.
Xu L, et al. Among authors: sun t.
J Thorac Cardiovasc Surg. 2025 Jan;169(1):242-253.e4. doi: 10.1016/j.jtcvs.2024.05.006. Epub 2024 May 17.
J Thorac Cardiovasc Surg. 2025.
PMID: 38763304
Clinical Trial.